rheumatoid arthritis vaccine (CEL-4000) / CEL-SCI - LARVOL DELTA

Current status of immunological therapies for rheumatoid arthritis with a focus on antigen-specific therapeutic vaccines. (PubMed, Front Immunol) - "Unlike these treatments, a therapeutic vaccine, such as CEL-4000, helps balance adaptive immune homeostasis by promoting antigen-specific regulatory rather than inflammatory responses, and hence modulates the immunopathological course of RA...Human trials of such a therapy will require alternative approaches in clinical trial design and implementation for determining safety, toxicity, and efficacy. These approaches include adaptive design (such as the Bayesian optimal design (BOIN), currently employed in oncological clinical studies), and the use of disease-related biomarkers as indicators of treatment success."

Journal • Review • Immunology • Inflammation • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology

CEL-SCI’s LEAPS Vaccine Offers Promising New Paradigm to Treat Rheumatoid Arthritis: Published in Frontiers in Immunology (Businesswire) - "CEL-SCI Corporation...announced the peer reviewed scientific journal Frontiers in Immunology published an article regarding CEL-SCI’s Ligand Epitope Antigen Presentation System (LEAPS) technology...CEL-SCI’s LEAPS team, along with outside collaborators from U.S. and Europe, reviewed published/presented results from pre-clinical animal model of antigen-specific LEAPS therapeutic vaccines, such as CEL-4000 and CEL-5000, made specific for the treatment of RA, and compared these findings with published results of other RA-therapies that either suppress or alter the immune response in order to treat RA...The authors also emphasized that the most appropriate way to advance the LEAPS vaccines to the clinic would be an adaptive study design for clinical trials, enrollment of patients with early-stage RA, and using the Bayesian optimal design model, currently used in oncology studies, as well as the use of disease-related biomarkers to ascertain responsiveness..."

Preclinical • Rheumatoid Arthritis

Vaccination by Two DerG LEAPS Conjugates Incorporating Distinct Proteoglycan (PG, Aggrecan) Epitopes Provides Therapy by Different Immune Mechanisms in a Mouse Model of Rheumatoid Arthritis. (PubMed, Vaccines (Basel)) - "LEAPS (Ligand Epitope Antigen Presentation System) DerG peptide conjugate vaccines were prepared using epitopes from PG that elicit immune responses in RA patients: epitope PG70 (DerG-PG70, also designated CEL-4000) and the citrullinated form of another epitope (PG275Cit)...Similarly, cytokines secreted by CD4+ cells of unvaccinated GIA mice, differentiated in vitro to Th2 cells and treated with either or both DerG vaccine peptides, exhibited an anti-inflammatory (IL-4, IL-10) profile. These results suggest that the two peptides elicit different therapeutic immune responses by the immunomodulation of disease-promoting pro-inflammatory responses and that the combination of the two LEAPS conjugates may provide broader epitope coverage and, in some cases, greater efficacy than either conjugate alone."

Journal • Preclinical • Immune Modulation • Immunology • Inflammation • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology • CD4 • IFNG • IL10 • IL17A • IL4

CEL-SCI’s scientific review on inflammatory disease therapies published in peer reviewed journal “International Immunopharmacology” (Businesswire) - "CEL-SCI Corporation...today announced that a review titled, 'Lessons From Next Generation Influenza Vaccines For Inflammatory Disease Therapies' was published in the peer reviewed scientific Journal International Immunopharmacology....The authors propose that treating autoimmune and inflammatory diseases using a T cell approach...ablation of potentially harmful cytokines, pathways or cells, offers advantages over the approach used currently...Based on the results of the Uni-Flu experiments, the CEL-2000 and CEL-4000 LEAPS...therapeutic antigen specific vaccines were developed for treatment of rheumatoid arthritis."

Review

CEL-SCI collaborators presents data for new vaccine in the treatment of rheumatoid arthritis at the International Conference on Immunity and Immunochemistry meeting (Businesswire) - "CEL-SCI Corporation...announced that one of its key collaborators from Rush University Medical center, Dr. Adrienn Markovitz...presented new LEAPS data at i-Chem2019, International Conference on Immunity and Immunochemistry in San Francisco, California on Wednesday July 3, 2019. The title of her presentation was 'Vaccination with DerG LEAPS peptide conjugates incorporating distinct PG (aggrecan) epitopes protects by different immune mechanisms in the PG G1 domain induced mouse model of rheumatoid arthritis'....The conclusion...was that vaccination with DerG LEAPS conjugates of distinct PG epitopes alone or together were effective...CEL-SCI intends to file an IND application with the U.S. Food and Drug Administration."

IND • Preclinical

CEL-SCI presents new data for its LEAPS vaccine in the treatment of rheumatoid arthritis at the American Association of Immunologists 103rd annual meeting (GlobeNewswire) - "CEL-SCI Corporation...announced today that Daniel Zimmerman, Ph.D....presented new LEAPS data at the American Association of Immunologists 103th Annual Meeting (Immunology 2019) in San Diego, California on Saturday, May 11, 2019. The title of his presentation is 'Therapeutic vaccination by two DerG LEAPS conjugates incorporating different PG (aggrecan) epitopes protect by different immune mechanisms in the PG G1 domain induced mouse model of rheumatoid arthritis'....'Both CEL-4000 (DerG-PG70)...LEAPS vaccines are therapeutic in the GIA model of RA with high efficacy'...Upon completion of preclinical and Investigational New Drug (IND) enabling studies...CEL-SCI intends to file an IND application with the U.S. Food and Drug Administration."

IND • Preclinical

Newly added product (Businesswire) - Preclinical, Rheumatoid arthritis

Pipeline update

U.S. Patent Office issues CEL-SCI two patents for its LEAPS vaccine platform technology (Businesswire) - "CEL-SCI Corporation...today announced the U.S. Patent and Trademark Office has issued two new U.S. patents for the Company’s LEAPS platform technology....The LEAPS platform technology is currently being developed as a therapeutic vaccine for rheumatoid arthritis (RA)...Upon completion of preclinical and Investigational New Drug (IND) enabling studies for the LEAPS-based rheumatoid arthritis vaccine candidate CEL-4000, CEL-SCI intends to file an IND application with the U.S. Food and Drug Administration."

IND • Patent